Pozen Seeks FDA Approval for Migraine Drug

Aug. 8–Pozen launched its third attempt to win regulatory approval for an experimental migraine drug.

Following two rejections, for experimental treatments known as MT100 and MT300, the Chapel Hill drug development company said Monday that it submitted MT400 for approval with the Food and Drug Administration. The experimental drug’s proposed brand name is Trexima.

GlaxoSmithKline has the rights to market and manufacture Trexima. The British pharmaceutical giant, which has a U.S. headquarters in Research Triangle Park and employs about 6,000 in the Triangle, has agreed to pay Pozen $20 million once the FDA accepts the regulatory filing.

—–

To see more of The News & Observer, or to subscribe to the newspaper, go to http://www.newsobserver.com.

Copyright (c) 2005, The News & Observer, Raleigh, N.C.

Distributed by Knight Ridder/Tribune Business News.

For information on republishing this content, contact us at (800) 661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-6515, or e-mail reprints@krtinfo.com.

POZN, GSK,